Cardiovascular Risk Factors After Single Pancreas Transplantation (Diamant)
Diabetes Type 1, Endothelial Dysfunction
About this trial
This is an interventional basic science trial for Diabetes Type 1 focused on measuring Diabetes type 1, Endothelial dysfunction, Pancreas transplantation
Eligibility Criteria
Inclusion Criteria:
- Patients with type 1 diabetes accepted for the waiting list for single pancreas transplantation
- Healthy volunteers (non-diabetic, non-transplanted)
- Over 18 years of age
- Signed informed consent
Exclusion Criteria:
- Non-functioning pancreas graft (defined as HbA1c ≥ 6.5 % with the need of insulin injections and fasting C-peptide concentration < 300 pmol/L).
- Active infection
- Active autoimmune disease other than diabetes
- Severe liver disease
Sites / Locations
- Oslo University Hospital, Rikshospitalet
Arms of the Study
Arm 1
Experimental
Single pancreas transplantation
This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.